We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Viropharma Incorporated (MM) | NASDAQ:VPHM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 49.98 | 0 | 01:00:00 |
Actelion Ltd. (ALIOF) recently announced that it will initiate a phase III development program with its clostridium difficile-associated diarrhea (CDAD) candidate, cadazolid.
The multi-center, randomized, double-blind studies will evaluate the safety and efficacy of cadazolid (250 mg, administered orally, twice daily) as compared to ViroPharma’s (VPHM) Vancocin (125 mg, administered orally, four times daily) in CDAD patients for 10 days.
This program comprises two similar studies which will evaluate whether the clinical response of cadazolid is non-inferior to Vancocin in CDAD patients and whether administration of cadazolid is superior to Vancocin in sustained clinical response. Enrolment of 1250 patients globally for the program is expected to start at the end of 2013.
The decision to advance the candidate into late-stage development was based on an exploratory phase II dose-finding study. Cadazolid was studied in a phase II multi-center, double-blind, randomized, active reference, parallel group, therapeutic exploratory study. Three doses of cadazolid (administered orally, twice daily) were evaluated for efficacy, safety and tolerability for 10 days with Vancocin as an active reference (125 mg administered orally, four times daily).
Results showed that the effect of all doses of cadazolid were either numerically similar or better than Vancocin on primary endpoints, which included CDAD cure rates as well as sustained cure rates.
Earlier this month, Actelion was in the news when it presented encouraging efficacy data on its pulmonary arterial hypertension (PAH) candidate, Opsumit at the European Society of Cardiology from a pivotal phase III study, SERAPHIN.
Actelion currently carries a Zacks Rank #1 (Strong Buy). Other stocks that look equally attractive in the pharma space include Biogen Idec Inc. (BIIB) and Affymetrix Inc. (AFFX).
1 Year Viropharma Incorporated (MM) Chart |
1 Month Viropharma Incorporated (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
